GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Total Non-Current Liabilities History
[Consolidated]
Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
---|---|---|---|---|---|
Total Non-Current Liabilities | ₹457 Cr | ₹489 Cr | ₹90 Cr | ₹94 Cr | ₹80 Cr |
What is the latest Total Non-Current Liabilities ratio of GLAND PHARMA ?
Year | Total Non-Current Liabilities |
---|---|
Mar2025 | ₹457 Cr |
Mar2024 | ₹489 Cr |
Mar2023 | ₹90 Cr |
Mar2022 | ₹94 Cr |
Mar2021 | ₹80 Cr |
How is Total Non-Current Liabilities of GLAND PHARMA Trending?
Years | Total Non-Current Liabilities | % Change | |
---|---|---|---|
Mar2025 | ₹457 Cr | -6.41 | |
Mar2024 | ₹489 Cr | 444.83 | |
Mar2023 | ₹90 Cr | -4.57 | |
Mar2022 | ₹94 Cr | 17.01 | |
Mar2021 | ₹80 Cr | - |
Compare Total Non-Current Liabilities of peers of GLAND PHARMA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLAND PHARMA | ₹34,039.4 Cr | 1.9% | 9.6% | 3.7% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹409,219.0 Cr | 2.5% | 4.1% | -0.8% | Stock Analytics | |
DIVIS LABORATORIES | ₹175,227.0 Cr | 0.5% | -2.9% | 35.7% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹126,643.0 Cr | 6.2% | 9.3% | 17.9% | Stock Analytics | |
CIPLA | ₹125,541.0 Cr | 4.9% | 2.9% | 1.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹106,063.0 Cr | 2.1% | 1.2% | -5% | Stock Analytics |
GLAND PHARMA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLAND PHARMA | 1.9% |
9.6% |
3.7% |
SENSEX | -1.2% |
-3% |
-0.2% |
You may also like the below Video Courses